EANO guideline on the diagnosis and treatment of vestibular schwannoma

Roland Goldbrunner(University of Cologne), Michael Weller(University of Zurich), Jean Régis, Morten Lund‐Johansen(University of Bergen), Pantelis Stavrinou(University of Cologne), David Reuß(Heidelberg University), D. Gareth Evans(University of Manchester), Florence Lefranc(Erasmus Hospital), Kita Sallabanda(Universidad Complutense de Madrid), Andrea Falini(Vita-Salute San Raffaele University), Patrick Axon(Cambridge University Hospitals NHS Foundation Trust), Olivier Sterkers(Sorbonne Université), Laura Fariselli(Fondazione IRCCS Istituto Neurologico Carlo Besta), Wolfgang Wick(Heidelberg University), Joerg-Christian Tonn(Ludwig-Maximilians-Universität München)
Neuro-Oncology
August 27, 2019
Cited by 430Open Access
Full Text

Abstract

The level of evidence to provide treatment recommendations for vestibular schwannoma is low compared with other intracranial neoplasms. Therefore, the vestibular schwannoma task force of the European Association of Neuro-Oncology assessed the data available in the literature and composed a set of recommendations for health care professionals. The radiological diagnosis of vestibular schwannoma is made by magnetic resonance imaging. Histological verification of the diagnosis is not always required. Current treatment options include observation, surgical resection, fractionated radiotherapy, and radiosurgery. The choice of treatment depends on clinical presentation, tumor size, and expertise of the treating center. In small tumors, observation has to be weighed against radiosurgery, in large tumors surgical decompression is mandatory, potentially followed by fractionated radiotherapy or radiosurgery. Except for bevacizumab in neurofibromatosis type 2, there is no role for pharmacotherapy.


Related Papers

No related papers found

Powered by citation graph analysis